Healthcare Investment Access (HIA) 2025/2026: Nordic Excellence, Global Opportunity
Where Nordic healthcare ventures meet global investors. Sharpen your pitch, elevate your presence, and step into the spotlight.
HIA’s mission is straightforward: shorten the path to investor readiness and help Nordic Healthcare entrepreneurs step confidently onto the global stage.
Since its launch in November 2024, HIA has showcased the best of Nordic healthcare innovation—companies with strong science, practical design, and teams who deliver. We provide the stage and the spotlight; founders turn visibility into execution.
The HIA program is an initiative by DNB Carnegie | Back Bay Partnership, in collaboration with Innovation Norway.
For 2025/2026 HIA is powered together with Ergo;ego, Insider Group, Nasdaq, the Norwegian Consulate General in New York, and Oslo Cancer Cluster.
The program is also supported by Aleap, Biotech North, Eitri, HAI, The Life Science Cluster, Luma Group, Norinnova, Norway Health Tech, the Norwegian Embassy in Bern, and Spark.
The HIA program for 2025/2026 will help the participants to:
- Connect directly with leading international investors, venture funds, and strategic partners.
- Gain expert guidance on how to position your company for global capital, including tailored insights into investor expectations outside the Nordic region.
- Receive a 360° Review & Mentoring — A comprehensive, multi-disciplinary evaluation across clinical, commercial, regulatory, and financing dimensions. Identify blind spots, align priorities, and sharpen investor readiness.
- Maximize visibility through curated investor interactions and spotlight moments at premier events, including the:
- DNB Carnegie Nordic Healthcare Conference in Oslo (Nov 2025)
- European Healthcare Investor Forum In Zurich (Feb 2026)
- Nordic-American Healthcare Conference in New York (Mar 2026)
Introducing the 2025/2026 HIA Cohort:
Excellence, Execution, Momentum
AKIGAI has discovered that EGFR inhibitors act as an “off switch” for neuropathic pain (NP) in roughly 70% of patients by targeting damaged pain fibers while sparing the central nervous system. Its lead candidate, AKI007, is a dosereduced, reformulated tablet with four layers of market protection. The company plans to advance AKI007 into a Phase III trial in Complex Regional Pain Syndrome (CRPS) in 2026, alongside a Phase II basket study across additional NP indications.
DoMore Diagnostics uses AI-driven digital biomarkers to guide personalized treatment decisions. Its technology predicts patient outcomes directly from routine tumor tissue slides and integrates seamlessly into existing pathology workflows. The lead product, Histotype Px® Colorectal, is a CE‑marked biomarker for Stage II and III colorectal cancer that informs adjuvant chemotherapy decisions after surgical resection.
ImmunoQuest Therapeutics is a preclinical biotechnology company developing next‑generation ADCs targeting p95HER2, a tumor‑specific HER2 isoform that drives metastasis and resistance to HER2 therapies. The company’s lead program, NAZ‑001, is a first‑in‑class ADC designed to deliver potent cytotoxic payloads with precision across HER2‑altered tumors where current therapies fail.
Node Pharma is a Norwegian radiopharmaceutical company developing first‑in‑class alpha therapies for cancer patients with limited treatment options. Its lead candidate, NODE101, uses a transarterial nanomedicine approach to deliver Radium‑223 directly to liver tumors, aiming for greater precision and safety than current beta‑based therapies. The company is advancing toward a Phase 1 clinical study in 2026 and building a scalable platform with global potential.
Rab Diagnostics develops precision biomarker solutions to support nextgeneration targeted chemotherapies, including ADCs. Its proprietary RabCancer platform establishes a new standard for predicting response to ADC therapy. Leveraging deep expertise in intracellular drug trafficking, Rab partners with biopharma companies to accelerate clinical development and deliver precision diagnostics to cancer patients.
ROPCA is transforming arthritis imaging with a robotic, AI‑driven self‑service ultrasound station that automates exams, removes operator dependency, and delivers consistent, high‑quality imaging. The system is already in paid use at the Mayo Clinic and with key opinion leaders across Germany, Austria, and Denmark. The company is targeting FDA clearance in the first half of next year, alongside a planned VA test agreement to support broader U.S. adoption.
Thelper AS has developed binders targeting a viral‑derived protein that is highly and selectively expressed in aggressive cancers. These binders enable the creation of highly potent precision medicines with improved safety profiles compared to existing therapies. The company is building a platform of first‑ and best‑in‑class targeted oncology therapeutics while maintaining a focus on cost‑efficiency and early exit opportunities for investors.
Tribune Therapeutics is a Scandinavian preclinical biotech company developing novel treatments for fibrotic diseases. Its lead compound targets the CCN protein family, overcoming historical challenges that limited earlier therapeutic approaches. The program demonstrates broad efficacy in kidney and lung models, supported by a clear biomarker strategy for upcoming clinical trials. Tribune has raised EUR 37M from leading Nordic and UK investors.
